Avalo Therapeutics Financial Overview
Avalo Therapeutics's market cap is currently $349.08M. The company's EPS TTM is $-2.19; its P/E ratio is -2.17; Avalo Therapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-1.37. See an overview of income statement, balance sheet, and cash flow financials.
